VIVUS (VVUS) Qsymia Prescriptions Pop Following Thanksgiving Glut (ARNA) (OREX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Notable ETF Movers of the Day 12/10: (IBB) (FXI) Higher; (DBA) Lower
December 10, 2012 12:52 PM ESTGainers:
iShares Nasdaq Biotechnology (Nasdaq: IBB) gained 1.5 percent to 138.9 with broad strength across the sector. VIVUS, Inc. (Nasdaq: VVUS) was among the winners, gaining 4 percent on news sales of... More
VIVUS, Inc. (VVUS) Begins Qsymia Free Trial Offer Program (CVS) (WAG)
November 26, 2012 8:34 AM ESTOn November 19, 2012, VIVUS, Inc., initiated the Qsymia Get Started! Free Trial Offer Program. The Company is offering eligible patients a Free Trial Offer on a valid prescription for up to a 14 capsule quantity of the Qsymia Starting Dose, 3.75 mg/23 mg (phentermine and topiramate extended-release). Eligible patients are able to receive up to 14 capsules of Qsymia... More
